AesthetiCare and Aesthetic Technology Ltd strengthen collaboration

AesthetiCare, a division of speciality dermatology company Ferndale Pharmaceuticals Ltd, and Aesthetic Technology Ltd, the developers and manufacturers of Dermalux LED phototherapy systems, are pleased to announce they have strengthened their collaboration.

Ferndale Pharmaceuticals now has 30% of the Aesthetic Technology shares, which will allow AesthetiCare to further integrate Dermalux into its aesthetic skin system portfolio and Aesthetic Technology to accelerate its expansion in the professional beauty and spa sectors. The combined teams will work closely together to provide the highest levels of clinical and business support to its existing and new customers. The new corporate joint venture will utilise the enhanced financial strength and operational infrastructures Ferndale can provide, supporting the exciting growth of Dermalux and it's already developing international presence. The wider experience of the Ferndale Pharma Group Inc. USA will also prove a valuable resource with the latter. With an exciting pipeline of dermatological product and business development opportunities the future for the two companies and their collective customers is bright.

Roger Bloxham, managing director of Ferndale Pharmaceuticals Ltd and AesthetiCare said, "We are delighted to have invested in Aesthetic Technology Ltd; such an exciting and innovative company that have already made a great impact in the UK aesthetic market, and have excellent international expansion and product development opportunities. They are fantastic people to work with, we share the same goals of evidence-based treatments providing natural, great looking skin and long lasting results, and look forward to delivering these to skin clinics together in a strengthened collaboration."

Huw Anthony, managing director of Aesthetic Technology Ltd said, “Having enjoyed working closely over the past 12 months, the opportunity to join forces on a formal commercial basis with AesthetiCare was far too good to miss, and we are proud to welcome them as shareholders in the business. In addition to the obvious appeal in the UK, to be able to work alongside Ferndale Pharma Group Inc. USA on an international basis is a fantastic development and one that strengthens the Dermalux brand in every respect. We have become great friends with Roger, Roisin and the team at AesthetiCare and look forward with anticipation and excitement as to what the future holds as we work together to develop existing and new Dermalux systems.”